FDA’s New Enforcement Memo Opens the Door for CBD Under Medicare — What It Says and What It Doesn’t
This article contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you.
A two-page memo from FDA Commissioner Marty Makary has quietly reshaped the regulatory terrain for hemp-derived CBD. In the memo — addressed to the agency’s deputy commissioner for human foods and the acting director of the Center for Drug Evaluation and Research — Makary wrote that the FDA “does not intend to enforce” specific provisions of the Federal Food, Drug, and Cosmetic Act against orally administered hemp-derived CBD products, provided those products meet certain baseline requirements.
The practical implication is significant: FDA-regulated products containing cannabidiol are now treated, in the agency’s own language, as “subject to the same legal and regulatory requirements as other FDA-regulated products.” That framing is a meaningful departure from the agency’s long-standing posture of treating CBD as categorically distinct from other dietary ingredients — a position rooted in Epidiolex’s approval as a prescription drug and the resulting exclusion of CBD from conventional supplement channels.
What the Memo Actually Does
The enforcement memo does not legalize CBD as a dietary supplement. It does not create a new regulatory pathway. It does not override existing law. What it does is signal that the executive branch under the current administration is not prioritizing enforcement against orally administered hemp-derived CBD products that otherwise comply with applicable regulations.
That distinction matters. The FDA’s formal regulatory position — that CBD cannot be legally marketed as a dietary supplement due to the prior drug exclusion rule under the FDCA — remains unchanged on paper. What has changed is the agency’s stated enforcement intent. For manufacturers and retailers of oral CBD products, the memo provides meaningful operational breathing room even as it leaves the underlying legal question unresolved.
Jim Higdon, co-founder and chief communications officer for Cornbread Hemp — one of the suppliers participating in the CMS Medicare CBD pilot program — characterized the development positively. “This is a sign that the executive branch is becoming comfortable with hemp-derived products,” Higdon told Marijuana Moment following the memo’s release.
The Medicare Connection
The timing of the FDA memo is closely linked to the April 2026 launch of the CMS Medicare CBD pilot program. For CMS to formally cover hemp-derived CBD products for eligible Medicare beneficiaries, the FDA needed to provide at least implicit clearance that such products would not face agency enforcement action during the pilot period.
The enforcement memo effectively provides that clearance. Without it, the Medicare pilot would have occupied a deeply uncomfortable regulatory gray zone — with one federal agency (CMS) actively funding the use of products that another federal agency (FDA) theoretically retained the authority to pursue enforcement action against.
The memo resolves that tension, at least functionally. It establishes a working federal consensus that oral hemp-derived CBD products — the specific format covered under the Medicare pilot — will not face FDA enforcement while the administration continues to evaluate a longer-term regulatory framework.
What Compliance Still Requires
The enforcement memo is not a blanket clearance. Makary’s language is specific: it applies to products that otherwise comply with applicable FDA requirements. In practice, that means:
- No unapproved drug claims
- Accurate labeling and ingredient disclosure
- No adulteration or contamination
- Compliance with basic safety standards
Brands making explicit medical claims — asserting that a CBD product diagnoses, treats, cures, or prevents any disease — remain firmly within FDA’s enforcement crosshairs. The memo changes nothing about the prohibition on unsubstantiated therapeutic claims.
For compliant brands already operating to these standards, the enforcement memo is functionally positive. For brands that have relied on loose labeling and vague wellness language, the memo is a reminder that enforcement of labeling and claims standards remains active.
What Comes Next
Industry analysts are watching the White House OMB review of the FDA’s full CBD compliance and enforcement policy, which is currently underway. The enforcement memo appears to be a precursor — clearing the path for the Medicare pilot while a more comprehensive regulatory framework works its way through the administrative process.
The shape of that framework, when it emerges, will determine whether the current enforcement restraint becomes codified policy or remains subject to revision under future administrations. In the meantime, the memo represents the most concrete federal signal in favor of CBD’s legal market position since the 2018 Farm Bill.
This article is for informational purposes only and does not constitute medical or legal advice. CBD products have not been evaluated by the Food and Drug Administration for the diagnosis, treatment, prevention, or cure of any disease or condition. Individual results may vary. Consult a qualified healthcare provider before using any CBD or hemp-derived product.
Learn more:
